Zacks: Brokers Count on Acutus Medical, Inc. (NASDAQ: AFIB) to Report Earnings Per Share of $ 0.71

Fairness analysis analysts forecast Acutus Medical, Inc. (NASDAQ: AFIB) to submit earnings per share (EPS) of ($ 0.71) for the present fiscal quarter, Zacks experiences. Two analysts supplied earnings estimates for Acutus Medical. The decrease estimate of EPS is ($ 0.84) and the upper is ($ 0.53). The corporate is anticipated to launch its subsequent quarterly outcomes on Thursday, March 4.

On common, analysts count on Acutus Medical to report annual earnings of ($ 60.79) per share for the present fiscal 12 months. For the subsequent fiscal 12 months, analysts predict the corporate will submit earnings of ($ 2.98) per share, with EPS estimates starting from ($ 3.12) to ($ 2.81). Zacks’ earnings per share calculations are a median primarily based on a survey of analysts who comply with Acutus Medical.

A number of fairness analysts not too long ago commented on AFIB shares. Canaccord Genuity reaffirmed a “maintain” ranking and set a goal worth of $ 30.00 on Acutus Medical shares in a report on Thursday, January 14. Zacks funding analysis upgraded Acutus Medical’s shares from a “promote” ranking to a “preserve” ranking in a report launched on Tuesday, January 19. Lastly, Financial institution of America downgraded Acutus Medical’s inventory from a “purchase” ranking to a “impartial” ranking and lowered its share worth goal from $ 38.00 to $ 30.00 in a analysis report on Thursday, January 14. Three fairness analysis analysts rated the inventory with a sustaining ranking and three gave the corporate’s inventory a purchase ranking. Acutus Medical at present has a consensus ranking of “Purchase” and a median worth goal of $ 34.75.

Quite a lot of institutional buyers and hedge funds have not too long ago purchased and offered shares within the firm. Roubaix Capital LLC acquired a brand new stake in Acutus Medical through the third quarter valued at roughly $ 1,275,000. American Worldwide Group Inc. acquired a brand new fairness curiosity in Acutus Medical through the third quarter valued at roughly $ 175,000. Wells Fargo & Firm MN acquired a brand new place in Acutus Medical within the third quarter valued at roughly $ 11,030,000. Index Enterprise Associates V Ltd acquired a brand new place in shares of Acutus Medical through the third quarter valued at roughly $ 4,875,000. Lastly, the California Public Workers Retirement System bought a brand new stake in Acutus Medical shares through the third quarter valued at roughly $ 630,000. Institutional buyers and hedge funds maintain 69.56% of the corporate’s shares.

(A d)

In partnership with superstar TV chef Cat Cora, HBIS is a house catering start-up that’s pulling all cylinders to capitalize on the rising demand for ready-to-go meals.

NASDAQ: AFIB open for $ 20.76 on Mondays. The 50-day shifting common share worth is $ 25.74. Acutus Medical has a 52 week minimal of $ 19.78 and a 52 week most of $ 38.99. The corporate has a present ratio of 10.89, a fast ratio of 10.21, and a debt ratio of 0.25.

About Acutus Medical

Acutus Medical, Inc., an arrhythmia administration firm, designs, manufactures and markets a line of instruments for catheter ablation procedures to deal with varied arrhythmias in the USA and world wide. It provides an AcQMap console and workstation, a complicated imaging, navigation and mapping system that enables physicians to map, deal with, crop and alter extra remedy as wanted; and the affected person electrode equipment required in every process to supply cardiac indicators, catheter location, and grounding of the AcQMap system.

Study extra: Intrinsic worth

Get a Free Copy of Zacks’ Analysis Report on Acutus Medical (AFIB)

For extra info on Zacks Funding Analysis’s analysis choices, go to Zacks.com

Earnings History and Estimates for Acutus Medical (NASDAQ: AFIB)

This immediate information alert was powered by storytelling know-how and monetary knowledge from MarketBeat to supply readers with the quickest, most correct experiences. This story was reviewed by the MarketBeat editorial staff previous to publication. Please ship any questions or feedback about this story to [email protected]

7 clear vitality shares with a shiny future

The controversy over renewable vitality (ie clear vitality) versus non-renewable vitality derived from fossil fuels was at all times going to be boiled down in {dollars} and cents. Since 2016, issues haven’t been straightforward for renewable vitality corporations. As the USA pushed for vitality independence, the Trump administration imposed tariffs on industrial segments. The sector has been the topic of much less favorable insurance policies from electrical energy regulators. As well as, competing vitality sources similar to coal have acquired extra help.

However a humorous factor has occurred prior to now 4 years. Renewable vitality corporations continued to develop. This perpetuates a pattern through which renewable vitality sources have gotten aggressive for companies. And that is a rising demand.

Probably the greatest elements of this business for buyers is that there are numerous methods to play the business. Along with photo voltaic and wind, hydrogen shares have gotten an intriguing technique to spend money on renewable vitality.

So, somewhat than seeing this election as a alternative between unhealthy and good, buyers ought to actually see it as a “good or higher” case. As a result of regardless of who wins the election, clear vitality shares will proceed to develop.

See the “7 Clear Vitality Shops with a Vibrant Future”.


Supply hyperlink

About Tina G.

Check Also

Bolt Biotherapeutics (NASDAQ: BOLT) lowered to “equal weight” at Morgan Stanley

Bolt Biotherapeutics (NASDAQ: BOLT) was downgraded by investment analysts at Morgan Stanley from an “overweight” …